Home Cart Sign in  
Chemical Structure| 2367004-54-2 Chemical Structure| 2367004-54-2

Structure of Zanzalintinib
CAS No.: 2367004-54-2

Chemical Structure| 2367004-54-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

XL-092 is an ATP-competitive inhibitor of multiple receptor tyrosine kinases including MET, VEGFR2, AXL and MER, with IC50 values of 15, 1.6, 3.4, and 7.2 nM, respectively, in cell-based assays.

Synonyms: XL092; JUN04542

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zanzalintinib

CAS No. :2367004-54-2
Formula : C29H25FN4O5
M.W : 528.53
SMILES Code : O=C(C1=CC2=C(OC3=CC=C(NC(C4(CC4)C(NC5=CC=C(C=C5)F)=O)=O)C=C3)C=CN=C2C=C1OC)NC
Synonyms :
XL092; JUN04542
MDL No. :MFCD34179545
InChI Key :JSPCKALGNNVYOO-UHFFFAOYSA-N
Pubchem ID :139350422

Safety of Zanzalintinib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of Zanzalintinib

RTK

Isoform Comparison

Biological Activity

Description
Zanzalintinib (XL092) is an orally active ATP-competitive inhibitor targeting multiple receptor tyrosine kinases (RTKs) such as MET, VEGFR2, AXL, and MER, with respective IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays. It demonstrates anti-tumor activity and holds promise for kinase-dependent diseases and conditions research [1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06568562 Metastatic Castration-resistan... More >>t Prostate Cancer Less << PHASE2 RECRUITING 2025-12-28 Huntsman Cancer Institute at U... More >>niversity of Utah, Salt Lake City, Utah, 84112, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.89mL

0.38mL

0.19mL

9.46mL

1.89mL

0.95mL

18.92mL

3.78mL

1.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories